Gabapentinoids and Risk of Hip Fracture
Authors' conclusion
In this case-case-time-control study of Australian residents hospitalized for hip fracture, gabapentinoid use was associated with an increased risk of hip fractures, especially in patients who were frail or had chronic kidney disease.
Study context
- Population
- Patients hospitalised for hip fracture in Victoria, Australia, March 2013–June 2018, with at least 1 gabapentinoid (pregabalin or gabapentin) prescription before fractureof 28,293 hip fracture patients
- Participants
- 2,946 patients
- Comparison
- Gabapentinoid dispensing in the index period vs the reference period
- Outcome
- Hip fracture
Methodological detailsconditional logistic regression, each index case matched with up to 5 controls from future cases of the same age and sex
- Conditional logistic regression
- Each index case matched with up to 5 controls from future cases of the same age and sex
Main finding
As reported in the abstract
Hip fracture: odds of gabapentinoid dispensing, index (1-60 days prefracture) vs reference (121-180 days prefracture) period
Gabapentinoid dispensingOdds ratio (95% CI)
Unadjusted
1.96(1.66–2.32)
Adjusted for exposure-time trend and concomitant CNS medications
1.30(1.07–1.57)
Further findings
Hip fracture in patients with Hospital Frailty Risk Score (HFRS) 5 and above (subgroup)
| OR (95% CI) | ||
|---|---|---|
| Gabapentinoid dispensing | 1.75 (1.31–2.33) | |
| 0.512Odds ratio (log scale) |
Hip fracture in patients with chronic kidney disease (CKD) (subgroup)
| OR (95% CI) | ||
|---|---|---|
| Gabapentinoid dispensing | 2.41 (1.65–3.52) | |
| 0.20.5125Odds ratio (log scale) |
Original publication
Gabapentinoids and Risk of Hip Fracture. JAMA Netw Open. Published 4 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →